Fredrik Klevebro1,2, Signe Friesland3, Mattias Hedman3, Jon A Tsai4, Mats Lindblad4, Ioannis Rouvelas4, Lars Lundell4, Magnus Nilsson4. 1. Division of Surgery, Department of Clinical Science Intervention and Technology, Karolinska Institutet, and Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden. fredrik.klevebro@ki.se. 2. Centre for Digestive Diseases, Karolinska University Hospital, K53 14186, Stockholm, Sweden. fredrik.klevebro@ki.se. 3. Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. 4. Division of Surgery, Department of Clinical Science Intervention and Technology, Karolinska Institutet, and Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.
Abstract
PURPOSE: Neoadjuvant chemoradiotherapy (nCRT) improves long-term survival for patients with esophageal cancer. On the other hand, there are indications that nCRT may increase the risk for postoperative morbidity. The aims of this study were to estimate the radiation exposure to the site of anastomosis on the gastric fundus and to assess whether nCRT affected the incidence or severity of cervical anastomotic complications. METHODS: A retrospective cohort of patients with cancer of the esophagus or gastroesophageal junction, who were reconstructed with cervical anastomosis. The planned radiation dose to the site of the cervical anastomosis on the gastric fundus was estimated for each patient. RESULTS: The analysis of the dose plans showed that 20 out of 22 (93 %) available patients received radiotherapy toward the planned site of the anastomosis in the region of the gastric fundus with doses ranging from 6 to 40 Gy. In the nCRT group, 12 out of 28 patients (43 %) had anastomotic complications compared to 16 out of 42 (38 %) in the non-RT group (p = 0.69). In the nCRT group, 39 % had anastomotic complications that led to a Clavien-Dindo grade of IVa or higher compared to 17 % in the non-RT group (p = 0.03). The OR for Clavien-Dindo grade IVa or worse was 6.0 (95 % CI 1.52-23.50). CONCLUSION: This small retrospective study suggests that nCRT exposes the future anastomotic site to doses of radiation that may impair healing of the subsequent cervical anastomosis. Our data further suggest that nCRT may increase the severity of cervical anastomotic complications, and this hypothesis needs to be tested in a large prospective study.
PURPOSE: Neoadjuvant chemoradiotherapy (nCRT) improves long-term survival for patients with esophageal cancer. On the other hand, there are indications that nCRT may increase the risk for postoperative morbidity. The aims of this study were to estimate the radiation exposure to the site of anastomosis on the gastric fundus and to assess whether nCRT affected the incidence or severity of cervical anastomotic complications. METHODS: A retrospective cohort of patients with cancer of the esophagus or gastroesophageal junction, who were reconstructed with cervical anastomosis. The planned radiation dose to the site of the cervical anastomosis on the gastric fundus was estimated for each patient. RESULTS: The analysis of the dose plans showed that 20 out of 22 (93 %) available patients received radiotherapy toward the planned site of the anastomosis in the region of the gastric fundus with doses ranging from 6 to 40 Gy. In the nCRT group, 12 out of 28 patients (43 %) had anastomotic complications compared to 16 out of 42 (38 %) in the non-RT group (p = 0.69). In the nCRT group, 39 % had anastomotic complications that led to a Clavien-Dindo grade of IVa or higher compared to 17 % in the non-RT group (p = 0.03). The OR for Clavien-Dindo grade IVa or worse was 6.0 (95 % CI 1.52-23.50). CONCLUSION: This small retrospective study suggests that nCRT exposes the future anastomotic site to doses of radiation that may impair healing of the subsequent cervical anastomosis. Our data further suggest that nCRT may increase the severity of cervical anastomotic complications, and this hypothesis needs to be tested in a large prospective study.
Authors: Ju Yang Park; Ho-Young Song; Jin Hyoung Kim; Jung-Hoon Park; Han Kyu Na; Yong Hee Kim; Seung-Il Park Journal: AJR Am J Roentgenol Date: 2012-05 Impact factor: 3.959
Authors: Dirk J Bosch; Christina T Muijs; Véronique E M Mul; Jannet C Beukema; Geke A P Hospers; Johannes G M Burgerhof; John Th M Plukker Journal: Ann Surg Oncol Date: 2013-10-08 Impact factor: 5.344
Authors: F Klevebro; G Johnsen; E Johnson; A Viste; T Myrnäs; E Szabo; A-B Jacobsen; S Friesland; J A Tsai; S Persson; M Lindblad; L Lundell; M Nilsson Journal: Eur J Surg Oncol Date: 2015-04-08 Impact factor: 4.424
Authors: Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham Journal: Lancet Oncol Date: 2005-09 Impact factor: 41.316
Authors: Christopher E Avendano; Patrick A Flume; Gerard A Silvestri; Lydia B King; Carolyn E Reed Journal: Ann Thorac Surg Date: 2002-03 Impact factor: 4.330
Authors: Mikael Lund; Gabriella Alexandersson von Döbeln; Magnus Nilsson; Reidar Winter; Lars Lundell; Jon A Tsai; Sigridur Kalman Journal: Radiat Oncol Date: 2015-01-13 Impact factor: 3.481
Authors: Florian Richter; Alexander Hendricks; Bodo Schniewind; Jochen Hampe; Nils Heits; Witigo von Schönfels; Benedikt Reichert; Katrin Eberle; Mark Ellrichmann; Petra Baumann; Jan-Hendrik Egberts; Thomas Becker; Clemens Schafmayer Journal: BJS Open Date: 2022-03-08